necitumumab,osimertinib
nippon kayaku,astrazeneca,eli lilly
['sclc', 'osimertinib', 'nsclc', 'necitumumab']
#cedarssinaicancer at #asco22. osimertinib + necitumumab in egfr-mutant #nsclc: final results from an etctn california cancer consortium phase i study with co-authors dr. sukhmani padda &amp; dr. karen reckamp is being presented. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.